Xarelto 20mg Tablet contains rivaroxaban, a direct oral anticoagulant that selectively inhibits factor Xa, a key enzyme in the coagulation cascade responsible for thrombin generation and clot formation. This medication is indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and for stroke prevention in patients with non-valvular atrial fibrillation. Rivaroxaban offers the advantage of oral administration with predictable pharmacokinetics and pharmacodynamics, eliminating the need for routine coagulation monitoring. The 20mg dosage is typically prescribed once daily with food to enhance absorption and ensure optimal therapeutic levels. Xarelto should be used with caution in patients with renal impairment, hepatic dysfunction, or those at increased risk of bleeding. Contraindications include active pathological bleeding and hypersensitivity to rivaroxaban. Common adverse effects may include bleeding complications, ranging from minor bruising to serious hemorrhage, and gastrointestinal disturbances. Patients are advised to inform healthcare providers of all concomitant medications to avoid potential drug interactions, particularly with other anticoagulants, antiplatelet agents, and certain CYP3A4 inhibitors or inducers. Adherence to prescribed dosing and regular medical follow-up are essential to maximize efficacy and minimize risks associated with Xarelto therapy.